中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (7): 538-545.doi: 10.19401/j.cnki.1007-3639.2020.07.009

• 综述 • 上一篇    下一篇

免疫治疗在卵巢癌中的应用研究进展

赵海云,吴小华   

  1. 复旦大学附属肿瘤医院妇瘤科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2020-07-30 发布日期:2020-08-06
  • 通信作者: 吴小华 E-mail: wu.xh@fudan.edu.cn

Research progress of immunotherapy in ovarian cancer

ZHAO Haiyun, WU Xiaohua   

  1. Department of Gynecology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2020-07-30 Published:2020-08-06
  • Contact: WU Xiaohua E-mail: wu.xh@fudan.edu.cn

摘要: 卵巢癌的临床早期症状不明显,筛查手段有限,就诊时常处于晚期阶段,5年生存率仅30%~45%,严重威胁着女性健康。免疫治疗尤其是免疫检查点抑制剂治疗因其持久的抗肿瘤效应已被批准用于晚期或复发性的多种类型癌症的治疗。目前免疫治疗的一些研究进展为卵巢癌患者的临床管理提供了新的机遇与挑战。

关键词: 卵巢癌, 免疫治疗, 免疫检查点抑制

Abstract: Five-year survival of ovarian cancer is 30%-45% for its non-obvious clinical symptoms, limited screening methods and advanced stage at initial diagnosis, which seriously threatens the health of women. Immunotherapy, especially immune checkpoint blockade, has been approved for treatment for patients with metastatic or recurrent multiple cancers for its durable anti-tumor effect. Also, the research progress of immunotherapy provides clinical management of ovarian cancer patients with new opportunities and challenges.

Key words: Ovarian cancer, Immunotherapy, Immune checkpoint blockade